Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database

Abstract Background Aminoglycosides have a concentration-dependent therapeutic effect when peak serum concentration (C max) reaches eight to tenfold the minimal inhibitory concentration (MIC). With an amikacin MIC of 8 mg/L, the C max should be 64–80 mg/L. This objective is based on clinical breakpo...

Full description

Bibliographic Details
Main Authors: Elsa Logre, Maya Enser, Sébastien Tanaka, Marie Dubert, Aurore Claudinon, Nathalie Grall, Hervé Mentec, Philippe Montravers, Olivier Pajot
Format: Article
Language:English
Published: SpringerOpen 2020-06-01
Series:Annals of Intensive Care
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13613-020-00685-5
id doaj-4cd191e0d23f43d994ede0cc398675f7
record_format Article
spelling doaj-4cd191e0d23f43d994ede0cc398675f72020-11-25T03:20:56ZengSpringerOpenAnnals of Intensive Care2110-58202020-06-011011810.1186/s13613-020-00685-5Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective databaseElsa Logre0Maya Enser1Sébastien Tanaka2Marie Dubert3Aurore Claudinon4Nathalie Grall5Hervé Mentec6Philippe Montravers7Olivier Pajot8CH Argenteuil, réanimation polyvalenteCH Argenteuil, réanimation polyvalenteCHU Bichat, réanimation chirurgicaleCHU Bichat, maladies infectieuses et tropicalesCH Argenteuil, microbiologieCHU Bichat, microbiologieCH Argenteuil, réanimation polyvalenteCHU Bichat, réanimation chirurgicaleCH Argenteuil, réanimation polyvalenteAbstract Background Aminoglycosides have a concentration-dependent therapeutic effect when peak serum concentration (C max) reaches eight to tenfold the minimal inhibitory concentration (MIC). With an amikacin MIC of 8 mg/L, the C max should be 64–80 mg/L. This objective is based on clinical breakpoints and not on measured MIC. This study aimed to assess the proportion of patients achieving the pharmacokinetic/pharmacodynamic (PK/PD) target C max/MIC ≥ 8 using the measured MIC in critically ill patients treated for documented Gram-negative bacilli (GNB) infections. Methods Retrospective analysis from February 2016 to December 2017 of a prospective database conducted in 2 intensive care units (ICU). All patients with documented severe GNB infections treated with amikacin (single daily dose of 25 mg/kg of total body weight (TBW)) with both MIC and C max measurements at first day of treatment (D1) were included. Results are expressed in n (%) or median [min–max]. Results 93 patients with 98 GNB-documented infections were included. The median C max was 55.2 mg/L [12.2–165.7] and the median MIC was 2 mg/L [0.19–16]. C max/MIC ratio ≥ 8 was achieved in 87 patients (88.8%) while a C max ≥ 64 mg/L was achieved in only 38 patients (38.7%). Overall probability of PK/PD target attainment was 93%. No correlation was found between C max/MIC ratio and clinical outcome at D8 and D28. Conclusion According to PK/PD parameters observed in our study, single daily dose of amikacin 25 mg/kg of TBW appears to be sufficient in most critically ill patients treated for severe GNB infections.http://link.springer.com/article/10.1186/s13613-020-00685-5PharmacokineticPharmacodynamicAmikacinIntensive care unit
collection DOAJ
language English
format Article
sources DOAJ
author Elsa Logre
Maya Enser
Sébastien Tanaka
Marie Dubert
Aurore Claudinon
Nathalie Grall
Hervé Mentec
Philippe Montravers
Olivier Pajot
spellingShingle Elsa Logre
Maya Enser
Sébastien Tanaka
Marie Dubert
Aurore Claudinon
Nathalie Grall
Hervé Mentec
Philippe Montravers
Olivier Pajot
Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
Annals of Intensive Care
Pharmacokinetic
Pharmacodynamic
Amikacin
Intensive care unit
author_facet Elsa Logre
Maya Enser
Sébastien Tanaka
Marie Dubert
Aurore Claudinon
Nathalie Grall
Hervé Mentec
Philippe Montravers
Olivier Pajot
author_sort Elsa Logre
title Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
title_short Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
title_full Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
title_fullStr Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
title_full_unstemmed Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
title_sort amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
publisher SpringerOpen
series Annals of Intensive Care
issn 2110-5820
publishDate 2020-06-01
description Abstract Background Aminoglycosides have a concentration-dependent therapeutic effect when peak serum concentration (C max) reaches eight to tenfold the minimal inhibitory concentration (MIC). With an amikacin MIC of 8 mg/L, the C max should be 64–80 mg/L. This objective is based on clinical breakpoints and not on measured MIC. This study aimed to assess the proportion of patients achieving the pharmacokinetic/pharmacodynamic (PK/PD) target C max/MIC ≥ 8 using the measured MIC in critically ill patients treated for documented Gram-negative bacilli (GNB) infections. Methods Retrospective analysis from February 2016 to December 2017 of a prospective database conducted in 2 intensive care units (ICU). All patients with documented severe GNB infections treated with amikacin (single daily dose of 25 mg/kg of total body weight (TBW)) with both MIC and C max measurements at first day of treatment (D1) were included. Results are expressed in n (%) or median [min–max]. Results 93 patients with 98 GNB-documented infections were included. The median C max was 55.2 mg/L [12.2–165.7] and the median MIC was 2 mg/L [0.19–16]. C max/MIC ratio ≥ 8 was achieved in 87 patients (88.8%) while a C max ≥ 64 mg/L was achieved in only 38 patients (38.7%). Overall probability of PK/PD target attainment was 93%. No correlation was found between C max/MIC ratio and clinical outcome at D8 and D28. Conclusion According to PK/PD parameters observed in our study, single daily dose of amikacin 25 mg/kg of TBW appears to be sufficient in most critically ill patients treated for severe GNB infections.
topic Pharmacokinetic
Pharmacodynamic
Amikacin
Intensive care unit
url http://link.springer.com/article/10.1186/s13613-020-00685-5
work_keys_str_mv AT elsalogre amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT mayaenser amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT sebastientanaka amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT mariedubert amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT auroreclaudinon amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT nathaliegrall amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT hervementec amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT philippemontravers amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
AT olivierpajot amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase
_version_ 1724615619713695744